Literature DB >> 15940250

Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals.

Hideaki Ishikawa1, Naohiro Tsuyama, Shangqin Liu, Saeid Abroun, Fu-Jun Li, Ken-Ichiro Otsuyama, Xu Zheng, Zi Ma, Yasuko Maki, Mohd S Iqbal, Masanori Obata, Michio M Kawano.   

Abstract

Interleukin-6 (IL-6) is a cytokine that regulates the proliferation of some tumor cells including multiple myeloma (MM). Ectopic expression of fibroblast growth factor receptor 3 (FGFR 3) associated with the chromosomal translocation, t(4;14)(p16.3;q32), is frequently found in MM, and therefore, has been implicated in the neoplastic transformation of this disease. Here, we show that IL-6 together with FGF enhanced proliferation of a myeloma cell line, KMS-11 carrying t(4;14)(p16.3;q32) and the FGFR 3-transfected U 266 myeloma cell line which ectopically expressed FGFR 3 but responded to neither IL-6 nor FGF alone. In KMS-11, IL-6 activated signal transducer and activator of transcription 3 (STAT 3) while FGF activated extracellular signal-regulated kinase 1/2 (ERK 1/2) and phosphatidylinositol (PI)-3 kinase. As both MEK inhibitors and a PI 3-kinase inhibitor abolished the effect of IL-6 and FGF, the activation of both the ERK 1/2 and PI 3-kinase signaling cascades is essential for the proliferation of KMS-11 enhanced by IL-6 and FGF. Furthermore, the FGF-induced activation of ERK 1/2 contributed to the serine phosphorylation of STAT 3, suggesting that the signaling crosstalk between the cytokine receptor, IL-6 receptor alpha/gp 130 and the growth factor receptor tyrosine kinase, FGFR 3. These results indicate that FGFR 3 plays a crucial role in the accelerated proliferation of MM carrying t(4;14)(p16.3;q32). Oncogene (2005) 24, 6328-6332.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15940250     DOI: 10.1038/sj.onc.1208782

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

2.  Gastrokine 1 inhibits the carcinogenic potentials of Helicobacter pylori CagA.

Authors:  Jung Hwan Yoon; Ho Suk Seo; Sung Sook Choi; Hyun Suk Chae; Won Seok Choi; Olga Kim; Hassan Ashktorab; Duane T Smoot; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Carcinogenesis       Date:  2014-09-19       Impact factor: 4.944

3.  Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.

Authors:  Wenjun Yu; Jianyong Li; Lijuan Chen
Journal:  Int J Clin Exp Med       Date:  2014-11-15

Review 4.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

5.  A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells.

Authors:  Lisa Salazar; Tamara Kashiwada; Pavel Krejci; Paul Muchowski; Daniel Donoghue; William R Wilcox; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

6.  Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

Authors:  Katia Todoerti; Valentina Barbui; Olga Pedrini; Marta Lionetti; Gianluca Fossati; Paolo Mascagni; Alessandro Rambaldi; Antonino Neri; Martino Introna; Luigia Lombardi; Josée Golay
Journal:  Haematologica       Date:  2009-08-27       Impact factor: 9.941

7.  Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Authors:  Yun Dai; Shuang Chen; Xin-Yan Pei; Jorge A Almenara; Lora B Kramer; Charis A Venditti; Paul Dent; Steven Grant
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

Review 8.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

9.  A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.

Authors:  Beata Holkova; Adriana Zingone; Maciej Kmieciak; Prithviraj Bose; Ashraf Z Badros; Peter M Voorhees; Rachid Baz; Neha Korde; Hui-Yi Lin; Jin-Qiu Chen; Michelle Herrmann; Liqiang Xi; Mark Raffeld; Xiuhua Zhao; Wen Wan; Mary Beth Tombes; Ellen Shrader; Caryn Weir-Wiggins; Heidi Sankala; Kevin T Hogan; Austin Doyle; Christina M Annunziata; Martha Wellons; John D Roberts; Daniel Sullivan; Ola Landgren; Steven Grant
Journal:  Clin Cancer Res       Date:  2015-10-07       Impact factor: 12.531

10.  Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.

Authors:  Ivyna Bong Pau Ni; Ng Ching Ching; Chang Kian Meng; Zubaidah Zakaria
Journal:  Hematol Rep       Date:  2012-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.